Company intelligence / Profile preview

PARI

Starnberg, Bavaria, Germany

Ownership: Private
Employees: ~500
Development stage: Other

Overview

PARI develops and markets a broad range of inhalation devices and drug-device combinations, with eFlow Technology forming the basis of advanced, clinic-validated aerosol delivery for several approved therapies in respiratory diseases. Company products are in wide clinical use, and PARI partners with pharma for device/drug co-development for new and existing inhaled treatments[1][2][4].

Therapeutic areas: Pulmonology
Modalities: DeviceBiologicSmall molecule
Industry: Therapeutic Medical Devices

Partnerships

NeupharmaVarious pharmaceutical partners for drug-device combinations

Beyond the preview

Go deeper on PARI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PARI.

Explore the full profile